

October 9, 2026
Mochida Pharmaceutical Co., Ltd.

Announcement of Master Distribution Agreement for ReFeel® Nerve Repair Solution in the U.S.

Mochida Pharmaceutical Co., Ltd. ("Mochida") announced that it has entered into a master distribution agreement with PBC Biomed Inc. (Memphis, Tennessee, U.S.; President: Paul Burke) for ReFeel®, a nerve repair solution, in the U.S.

Under this agreement, Mochida Medical USA, Inc. (Cordova, Tennessee, U.S.; President: Fumihiko Mori), a U.S. subsidiary of Mochida, will collaborate with PBC Biomed Inc. to commence full-scale sales of ReFeel®. PBC Biomed Inc. will work with multiple independent distributors across the U.S. to support and promote the sales of ReFeel®.

ReFeel® is a medical device that is a sheet material composed of sodium alginate and polyglycolic acid nonwoven fabric. Sodium alginate creates an environment favorable to nerve regeneration in the damaged nerve site, supporting the repair and regeneration of nerves. The polyglycolic acid nonwoven fabric ensures the flexibility and strength of the sheet material. ReFeel® is characterized by its applicability according to the condition of the nerve injury site and the ease of handling provided by its sheet format.

Through these initiatives in the U.S., Mochida aims to contribute to improving patients' quality of life (QOL) and to the further growth of its biomaterials business.

About PBC Biomed Inc.

PBC Biomed Inc. is a U.S. subsidiary of Pharmaceutical Business Consultants Limited trading as PBC Biomed, headquartered in Shannon, Ireland. PBC Biomed was founded in 2010 to drive innovation in medical devices, biomaterials, and pharmaceuticals by accelerating the commercialization of new technologies. Leveraging its extensive industry expertise, PBC Biomed collaborates with companies, physicians, universities, and other partners to drive innovation in life-changing medical technologies. Mochida has contracted PBC Biomed to manufacture ReFeel®.

Note: ReFeel® has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) but has not been approved in Japan.

Contact:

Mochida Pharmaceutical Co., Ltd.
Public Relations, Corporate Planning Department
Email: webmaster@mochida.co.jp

###

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
--